Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up

References

• Cancer Incidence in Sweden (2001) 1999. Statistics-Health and Diseases 2001:4. The National Board of Health and Welfare, Centre for Epidemiology, Stockholm, Sweden, .
   Google Scholar
• Borghede G, Hedelin H, Holmang S, Johansson KA, Sernbo G, Mercke C. Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland. Radiother Oncol 1997; 44: 245–50
   PubMed Web of Science ®Google Scholar
• Wahlgren T, Brandberg Y, Haggarth L, Hellstrom M, Nilsson S. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)Ir brachytherapy: A prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25. Int J Radiat Oncol Biol Phys 2004; 60: 51–9
   PubMed Web of Science ®Google Scholar
• Wahlgren T, Nilsson S, Ryberg M, Lennernas B, Brandberg Y. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: A prospective assessment of acute and late treatment toxicity. Acta Oncol 2005; 44: 633–43
   PubMed Web of Science ®Google Scholar
• Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035–41.
   PubMedGoogle Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341–6
   PubMed Web of Science ®Google Scholar
• Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18: 3352–9
   PubMed Web of Science ®Google Scholar
• Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766–71
   PubMed Web of Science ®Google Scholar
• Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 2001; 50: 1021–31
   PubMed Web of Science ®Google Scholar
• Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, et al. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 993–1002
   PubMed Web of Science ®Google Scholar
• Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316–81
   PubMed Web of Science ®Google Scholar
• Ljung G, Norberg M, Hansson H, de la Torre M, Egevad L, Holmberg L, et al. Transrectal ultrasonically-guided core biopsies in the assessment of local cure of prostatic cancer after radical external beam radiotherapy. Acta Oncol 1995; 34: 945–52
   PubMed Web of Science ®Google Scholar
• Hanks GE, Lee WR, Hanlon AL, Hunt M, Kaplan E, Epstein BE, et al. Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML. Int J Radiat Oncol Biol Phys 1996; 35: 861–8
   PubMed Web of Science ®Google Scholar
• Fransson P, Löfroth P-O, Franzén L, Henriksson R, Bergström P, Widmark A. Acute side effects after dose-escalation treatment of prostate cancer using the new urethral catheter BeamCath® technique. Acta Oncol 2001; 40: 756–65
   PubMedGoogle Scholar
• Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 2003;169:974–9; Discussion 979–80.
   PubMed Web of Science ®Google Scholar
• Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L. High dose-rate afterloading 192 Iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 1998; 41: 525–33
   PubMedGoogle Scholar
• Galalae RM, Loch T, Riemer B, Rzehak P, Kuchler T, Kimmig B, et al. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer. Strahlenther Onkol 2004; 180: 582–9
   PubMed Web of Science ®Google Scholar
• Pellizzon AC, Nadalin W, Salvajoli JV, Fogaroli RC, Novaes PE, Maia MA, et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol 2003; 66: 167–72
   PubMedGoogle Scholar
• Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 59: 684–90
   PubMedGoogle Scholar
• Stevens MJ, Stricker PD, Saalfeld J, Brenner PC, Kooner R, O'Neill GF, et al. Treatment of localized prostate cancer using a combination of high dose rate Iridium-192 brachytherapy and external beam irradiation: initial Australian experience. Australas Radiol 2003; 47: 152–60
   PubMedGoogle Scholar
• Deger S, Boehmer D, Turk I, Roigas J, Wernecke KD, Wiegel T, et al. High dose rate brachytherapy of localized prostate cancer. Eur Urol 2002; 41: 420–6
   PubMed Web of Science ®Google Scholar
• Martin T, Roddiger S, Kurek R, Dannenberg T, Eckart O, Kolotas C, et al. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 2004; 71: 35–41
   PubMedGoogle Scholar
• Astrom L, Pedersen D, Mercke C, Holmang S, Johansson KA. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 2005;74:157–61. Epub 2004 Nov 25.
   PubMed Web of Science ®Google Scholar
• Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1048–55
   PubMed Web of Science ®Google Scholar
• Syed AM, Puthawala A, Austin P, Cherlow J, Perley J, Tansey L, et al. Temporary iridium-192 implant in the management of carcinoma of the prostate. Cancer 1992; 69: 2515–24
   PubMed Web of Science ®Google Scholar
• Egawa S, Shimura S, Irie A, Kitano M, Nishiguchi I, Kuwao S, et al. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 2001; 31: 541–7
   PubMed Web of Science ®Google Scholar
• Jacobs DM, Vago JF, Weiss MA. Gleason grading of prostatic adenocarcinoma on fine-needle aspiration. Diagn Cytopathol 1989; 5: 126–33
   PubMedGoogle Scholar
• Maksem JA, Johenning PW. Is cytology capable of adequately grading prostate carcinoma? Matched series of 50 cases comparing cytologic and histologic pattern diagnoses. Urology 1988; 31: 437–44
   PubMedGoogle Scholar
• Borghede G, Hedelin H, Holmang S, Johansson KA, Aldenborg F, Pettersson S, et al. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 1997; 44: 237–44
   PubMed Web of Science ®Google Scholar
• Dinges S, Deger S, Koswig S, Boehmer D, Schnorr D, Wiegel T, et al. High-dose rate interstitial with external beam irradiation for localized prostate cancer – results of a prospective trial. Radiother Oncol 1998; 48: 197–202
   PubMedGoogle Scholar
• Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol 1998; 159: 1988–92
   PubMed Web of Science ®Google Scholar
• Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, et al. RTOG's first quality of life study–RTOG 90-20: A phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 901–6
   PubMed Web of Science ®Google Scholar
• Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient?. Br J Cancer 1988; 57: 109–12
   PubMed Web of Science ®Google Scholar
• da Silva FC. Quality of life in prostatic carcinoma. Eur Urol 1993; 24: 113–7
   PubMedGoogle Scholar
• Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, et al. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: The William Beaumont phase II dose-escalating trial. Int J Radiat Oncol Biol Phys 2000; 47: 343–52
   PubMed Web of Science ®Google Scholar
• Galalae RM, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52: 81–90
   PubMed Web of Science ®Google Scholar